作者:Kaplan Warren A
来源:[J].Globalization and Health(IF 1.485), 2006, Vol.2, pp.9PubMed
摘要:The ongoing policy debate about the value of communications technology in promoting development objectives is diverse. Some view computer/web/phone communications technology as insufficient to solve development problems while others view communications technology as assisting all...
作者:Kaplan Warren A , Beall Reed F
来源:[J].Journal of pharmaceutical policy and practice, 2017, Vol.10, pp.3PubMed
摘要:Lack of access to insulin and poor health outcomes are issues for both low and high income countries. This has been accompanied by a shift from relatively inexpensive human insulin to its more expensive analogs, marketed by three to four main global players. Nonetheless, patent-b...
作者:Kaplan Warren A , Kwan Gene F
来源:[J].Circulation, 2016, Vol.133 (21), pp.2076-85PubMed
摘要:Cardiovascular diseases (CVD) represent the highest burden of disease globally. Medicines are a critical intervention used to prevent and treat CVD. This review describes access to medication for CVD from a health system perspective and strategies that have been used to promote a...
作者:Kaplan Warren A , Chokshi Maulik
来源:[J].Health policy and planning, 2016, Vol.31 (7), pp.884-96PubMed
摘要:India's Universal Immunization Programme (UIP) provides basic vaccines free-of-cost in the public sector, yet national vaccination coverage is poor. The Government of India has urged an expanded role for the private sector to help achieve universal immunization coverage. We ...
作者:Kaplan Warren A , Ritz Lindsay Sarah ...
来源:[J].Health Policy, 2012, Vol.106 (3), pp.211-24PubMed
摘要:Review the literature on the impact of policies designed to enhance uptake of generic medicines in low and middle income countries (LMICs).;;We searched for publications related to generic medicines policies (January 2000-March 2010) and did a bibliometric, descriptive analysis o...
作者:Kaplan Warren A , Laing Richard
来源:[J].Health Policy and Planning(IF 3.056), 2003, Vol.18 (3), pp.237-48PubMed
摘要:Fees charged by drug regulatory authorities (DRAs) may be used as a policy instrument to speed up regulatory approval, to encourage retention of quality staff and to stimulate introduction of generics versus new chemical entities. Often, the cost recovery function of these regist...
作者:... Santa-Ana-Tellez Yared , Trout Clinton H , Kaplan Warren A
来源:[J].Health Policy and Planning, 2012PubMed
摘要:Public sector price analyses of antiretroviral (ARV) medicines can provide relevant information to detect ARV procurement procedures that do not obtain competitive market prices. Price benchmarks provide a useful tool for programme managers and policy makers to support such plann...


资源合作, +86-10-82896619   意见反馈